MYX mayne pharma group limited

Ann: Non-Executive Director appointment and retirement, page-17

  1. 309 Posts.
    lightbulb Created with Sketch. 304
    Totally agree with your thoughts on MYX.
    I think a few new holders would love to cash in on the sale of the Metrics Division and see a juicy special dividend.
    I personally would like to see the cash used to expand our Nextillis sales team. So far it is way below expectations, as it was expected to be EBIT positive within first year of approval. This has not been achieved.
    The licence to sell it has cost us dearly and it is expected to peak at 200 mil per year. We are nowhere near that as yet and will need a big push to get anywhere near that. At the current rate it will take years to reach breakeven.
    We have just seen 10 c wiped from the sp again, it seems that it was a pump and dump so that SR could claim his bonuses before he left. The timing of the sale , the timing of the announcement for his performance bonuses and now his resignation/ retirement all correlate to his self interest in milking all he could from this cash cow.
    If the cash is distributed, the value of the company will also decrease, pushing the share price even lower.
    Hopefully the new board can steer this company onto a positive path and move us thru to the next level . I still believe this stock has a huge upside if we can just get it right.
    GL and DYOR
    cheers
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.25
Change
-0.150(2.78%)
Mkt cap ! $426.5M
Open High Low Value Volume
$5.35 $5.41 $5.19 $1.239M 231.7K

Buyers (Bids)

No. Vol. Price($)
1 1000 $5.17
 

Sellers (Offers)

Price($) Vol. No.
$5.36 1000 1
View Market Depth
Last trade - 16.11pm 25/07/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.